Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3748/wjg.v23.i23.4181 http://scihub22266oqcxt.onion/10.3748/wjg.v23.i23.4181 C5483492!5483492 !28694658     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28694658 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       World+J+Gastroenterol 2017 ; 23 (23 ): 4181-4190 Nephropedia Template TP {{tp|p=28694658 |t=2017. Anti-steatotic and anti-fibrotic effects of the KCa3 1 channel inhibitor, Senicapoc, in non-alcoholic liver disease |pdf=|usr=}}{{28694658 }} gab.com Text Anti-steatotic and anti-fibrotic effects of the KCa3 1 channel inhibitor, Senicapoc, in non-alcoholic liver disease JO: World J Gastroenterol http://www.kidney.de/pget.php?&tw=1&pmid=28694658 #FOAvip AIM: To evaluate a calcium activated potassium channel (KCa3.1) inhibitor attenuates liver disease in models of non-alcoholic fatty liver disease (NAFLD). METHODS: We have performed a series of in vitro and in vivo studies using the KCa3.1 channel inhibitor, Senicapoc. Efficacy studies of Senicapoc were conducted in toxin-, thioacetamide (TAA) and high fat diet (HFD)-induced models of liver fibrosis in rats. Efficacy and pharmacodynamic effects of Senicapoc was determined through biomarkers of apoptosis, inflammation, steatosis and fibrosis. RESULTS: Upregulation of KCa3.1 expression was recorded in TAA-induced and high fat diet-induced liver disease. Treatment with Senicapoc decreased palmitic acid-driven HepG2 cell death. (P < 0.05 vs control) supporting the finding that Senicapoc reduces lipid-driven apoptosis in HepG2 cell cultures. In animals fed a HFD for 6 wk, co-treatment with Senicapoc, (1) reduced non-alcoholic fatty liver disease (NAFLD) activity score (NAS) (0-8 scale), (2) decreased steatosis and (3) decreased hepatic lipid content (Oil Red O, P < 0.05 vs vehicle). Randomization of TAA animals and HFD fed animals to Senicapoc was associated with a decrease in liver fibrosis as evidenced by hydroxyproline and Masson's trichrome staining (P < 0.05 vs vehicle). These results demonstrated that Senicapoc mitigates both steatosis and fibrosis in liver fibrosis models. CONCLUSION: These data suggest that Senicapoc interrupts more than one node in progressive fatty liver disease by its anti-steatotic and anti-fibrotic activities, serving as a double-edged therapeutic sword. Twit Text FOAVip Anti-steatotic and anti-fibrotic effects of the KCa3 1 channel inhibitor, Senicapoc, in non-alcoholic liver disease ????World J Gastroenterol http://www.kidney.de/pget.php?&tw=1&pmid=28694658 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28694658 #FOAvip English Wikipedia <ref>{{Cite pmid|28694658 }}</ref> Anti-steatotic and anti-fibrotic effects of the KCa3 1 channel inhibitor, Senicapoc, in non-alcoholic liver disease #MMPMID28694658 Paka L ; Smith DE ; Jung D ; McCormack S ; Zhou P ; Duan B ; Li JS ; Shi J ; Hao YJ ; Jiang K ; Yamin M ; Goldberg ID ; Narayan P World J Gastroenterol 2017[Jun]; 23 (23 ): 4181-4190 PMID28694658 show ga AIM: To evaluate a calcium activated potassium channel (KCa3.1) inhibitor attenuates liver disease in models of non-alcoholic fatty liver disease (NAFLD). METHODS: We have performed a series of in vitro and in vivo studies using the KCa3.1 channel inhibitor, Senicapoc. Efficacy studies of Senicapoc were conducted in toxin-, thioacetamide (TAA) and high fat diet (HFD)-induced models of liver fibrosis in rats. Efficacy and pharmacodynamic effects of Senicapoc was determined through biomarkers of apoptosis, inflammation, steatosis and fibrosis. RESULTS: Upregulation of KCa3.1 expression was recorded in TAA-induced and high fat diet-induced liver disease. Treatment with Senicapoc decreased palmitic acid-driven HepG2 cell death. (P < 0.05 vs control) supporting the finding that Senicapoc reduces lipid-driven apoptosis in HepG2 cell cultures. In animals fed a HFD for 6 wk, co-treatment with Senicapoc, (1) reduced non-alcoholic fatty liver disease (NAFLD) activity score (NAS) (0-8 scale), (2) decreased steatosis and (3) decreased hepatic lipid content (Oil Red O, P < 0.05 vs vehicle). Randomization of TAA animals and HFD fed animals to Senicapoc was associated with a decrease in liver fibrosis as evidenced by hydroxyproline and Masson's trichrome staining (P < 0.05 vs vehicle). These results demonstrated that Senicapoc mitigates both steatosis and fibrosis in liver fibrosis models. CONCLUSION: These data suggest that Senicapoc interrupts more than one node in progressive fatty liver disease by its anti-steatotic and anti-fibrotic activities, serving as a double-edged therapeutic sword. |*Gene Expression Regulation, Neoplastic [MESH] |Acetamides/*pharmacology [MESH] |Animals [MESH] |Apoptosis [MESH] |Biomarkers, Tumor/metabolism [MESH] |Diet, High-Fat [MESH] |Fibrosis [MESH] |Hep G2 Cells [MESH] |Humans [MESH] |Inflammation [MESH] |Intermediate-Conductance Calcium-Activated Potassium Channels/*antagonists & inhibitors/metabolism [MESH] |Liver Cirrhosis/metabolism [MESH] |Male [MESH] |Mice [MESH] |Mice, Inbred C57BL [MESH] |Non-alcoholic Fatty Liver Disease/*drug therapy [MESH] |Palmitic Acid [MESH] |Rats [MESH] |Rats, Wistar [MESH] |Thioacetamide [MESH] |Triphenylmethyl Compounds/*pharmacology [MESH]Anti-steatotic and anti-fibrotic effects of the KCa3 1 channel inhibit(epmc).pdf DeepDyve Pubget Overpricing